These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 36678729)

  • 1. Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations.
    Frézard F; Aguiar MMG; Ferreira LAM; Ramos GS; Santos TT; Borges GSM; Vallejos VMR; De Morais HLO
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes.
    Ramos GS; Vallejos VMR; Borges GSM; Almeida RM; Alves IM; Aguiar MMG; Fernandes C; Guimarães PPG; Fujiwara RT; Loiseau PM; Ferreira LAM; Frézard F
    Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases.
    Lanza JS; Pomel S; Loiseau PM; Frézard F
    Expert Opin Drug Deliv; 2019 Oct; 16(10):1063-1079. PubMed ID: 31433678
    [No Abstract]   [Full Text] [Related]  

  • 4. The Designing of a Gel Formulation with Chitosan Polymer Using Liposomes as Nanocarriers of Amphotericin B for a Non-invasive Treatment Model of Cutaneous Leishmaniasis.
    Gürbüz Çolak N; Çetin Uyanikgil EÖ; Özbel Y; Töz S
    Acta Parasitol; 2022 Sep; 67(3):1354-1363. PubMed ID: 35857275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
    Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
    Antimicrob Agents Chemother; 2002 Mar; 46(3):834-40. PubMed ID: 11850269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
    Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphotericin B: A drug of choice for Visceral Leishmaniasis.
    Kumari S; Kumar V; Tiwari RK; Ravidas V; Pandey K; Kumar A
    Acta Trop; 2022 Nov; 235():106661. PubMed ID: 35998680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome
    Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Alavijeh M; Silva-Pedrosa R; Antunes S; Mauricio I; Murdan S; Croft SL
    Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):223-228. PubMed ID: 29673889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, biodistribution, and activity of Amphotericin B-loaded nanocochleates on the Leishmania donovani murine visceral leishmaniasis model.
    Lipa Castro A; Pomel S; Cailleau C; Fournier N; Dennemont I; Loiseau PM; Barratt G
    Int J Pharm; 2022 Aug; 624():121985. PubMed ID: 35820519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.
    Yardley V; Croft SL
    Antimicrob Agents Chemother; 1997 Apr; 41(4):752-6. PubMed ID: 9087483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
    Gangneux JP; Sulahian A; Garin YJ; Derouin F
    Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution and
    Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
    Davidson RN; Croft SL; Scott A; Maini M; Moody AH; Bryceson AD
    Lancet; 1991 May; 337(8749):1061-2. PubMed ID: 1673494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations.
    Serrano DR; Hernández L; Fleire L; González-Alvarez I; Montoya A; Ballesteros MP; Dea-Ayuela MA; Miró G; Bolás-Fernández F; Torrado JJ
    Int J Pharm; 2013 Apr; 447(1-2):38-46. PubMed ID: 23438978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.
    Faustino C; Pinheiro L
    Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31906268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
    Tiphine M; Letscher-Bru V; Herbrecht R
    Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.
    Ruiz HK; Serrano DR; Dea-Ayuela MA; Bilbao-Ramos PE; Bolás-Fernández F; Torrado JJ; Molero G
    Int J Pharm; 2014 Oct; 473(1-2):148-57. PubMed ID: 24998510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
    Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
    Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion.
    Rochelle do Vale Morais A; Silva AL; Cojean S; Balaraman K; Bories C; Pomel S; Barratt G; do Egito EST; Loiseau PM
    Exp Parasitol; 2018 Sep; 192():85-92. PubMed ID: 30075233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.